Skip to search formSkip to main contentSkip to account menu

5 ML zoledronic acid 0.8 MG/ML Injection [Zometa]

Known as: Zometa 4 MG in 5 ML Injection, 5 ML Zometa 0.8 MG/ML Injection, Zometa 4 MG per 5 ML Injection 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (1)

5 ML zoledronic acid 0.8 MG/ML Injection
InjectionMannitolWaterZometa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
How cancer patients can lower the risk of bisphosphonate-related osteonecrosis of the jaw ( BRONJ )
  • 2018
  • Corpus ID: 53485629
What we know Bisphosphonate (BP) treatment is typically the first medicine used for patients with osteoporosis to slow the… 
2016
2016
Efecto citoprotector de la melatonina sobre fármacos antirreabsortivos
INTRODUCCION: La osteonecrosis mandibular es un efecto secundario que puede aparecer en aquellos pacientes que reciben… 
2013
2013
RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study
Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa®, ZA), routinely used to treat… 
Highly Cited
2012
Highly Cited
2012
Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
2012
2012
Zoledronic Acid
SummaryAbstractZoledronic acid (Zometa®), a third-generation amino-bisphosphonate, has been approved in the US, the EU and many… 
2008
2008
Sistemik olarak verilen zoledronik asidin (Zometa®), titanyum dental implantların osteointegrasyon düzeylerine etkisi
2004
2004
Zometa® (zoledronic acid) in patients with skeletal metastases secondary to breast cancer — a study of home versus hospital administration
2003
2003
Spotlight on Zoledronic Acid in the Management of Bone Metastases and Hypercalcemia of Malignancy
AbstractZoledronic acid (Zometa®) is an effective inhibitor of osteoclast-mediated bone resorption. Zoledronic acid demonstrated… 
2003
2003
Zoledronic acid (Zometa ® ), a third generation bisphosphonate, for prevention of skeletal complications due to bone metastases.
Summary This report summarises the results of the clinical development program of zoledronic acid (Zometa ® ), a third generation… 
2000
2000
Optimising treatment of bone metastases by Aredia™ and Zometa™
Metastatic bone disease develops as a result of the many interactions between tumour cells and bone cells. This leads to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)